Manoli I, Sysol JR, Epping MW, et al. FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. JCI Insight. 2018;3(23). doi:10.1172/jci.insight.124351.

Miller JW, Vandenberghe LH. Breaking and Sealing Barriers in Retinal Gene Therapy. Mol Ther. 2018;26(9):2081-2082. doi:10.1016/j.ymthe.2018.08.003.

Ikeda Y, Sun Z, Ru X, Vandenberghe LH, Humphreys BD. Efficient Gene Transfer to Kidney Mesenchymal Cells Using a Synthetic Adeno-Associated Viral Vector. J Am Soc Nephrol. 2018;29(9):2287-2297. doi:10.1681/ASN.2018040426.

Cox DBT, Gootenberg JS, Abudayyeh OO, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019-1027. doi:10.1126/science.aaq0180.

Lessard S, Francioli L, Alföldi J, et al. Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci. Proc Natl Acad Sci U S A. 2017;114(52):E11257-E11266. doi:10.1073/pnas.1714640114.

Gao X, Tao Y, Lamas V, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature. 2018;553(7687):217-221. doi:10.1038/nature25164.

Yu D, Khan OF, Suvà ML, et al. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A. 2017;114(30):E6147-E6156. doi:10.1073/pnas.1701911114.

Berger MF, Garraway LA. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am. 2009;23(3):397-414, vii. doi:10.1016/j.hoc.2009.03.005.

Lander ES. Eric S. Lander. Nat Rev Drug Discov. 2004;3(9):730. doi:10.1038/nrd1514.

Greulich H, Chen T-H, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2(11):e313. doi:10.1371/journal.pmed.0020313.